Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: BCYC

Group By Ticker
Sort By
Newest | Oldest
Read More
13 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For September 12, 2023

By Benzinga Insights
September 12, 11:00 AM
Upgrades RBC Capital upgraded the previous rating for Equinox Gold Corp (AMEX:EQX) from Underperform to Sector Perform. In…

$TKO

Read More
2 minute read
  • Analyst Ratings

Where Bicycle Therapeutics Stands With Analysts

By Benzinga Insights
September 7, 3:00 PM
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

BCYC

Read More
1 minute read
  • Analyst Ratings

Expert Ratings for Bicycle Therapeutics

By Benzinga Insights
August 4, 9:00 AM
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BCYC

Read More
3 minute read
  • Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights
July 13, 1:37 PM
Gainers Bicycle Therapeutics (NASDAQ:BCYC) stock moved upwards by 18.0% to $25.96 during Thursday’s regular session. As of 13:37…

APDN

Read More
2 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday

By Lisa Levin
July 13, 10:59 AM
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) gained 18% to $1.62. Nikola and Bayotech partnered to advance zero-emission hydrogen delivery.

ACMR

Read More
2 minute read
  • Earnings

Bicycle Therapeutics’s Return On Capital Employed Insights

By Benzinga Insights
May 17, 10:46 AM
Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $4.90 million. Earnings fell to a loss of…

BCYC

Read More
2 minute read
  • Analyst Ratings

14 Analysts Have This to Say About Bicycle Therapeutics

By Benzinga Insights
May 11, 11:02 AM
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BCYC

Read More
1 minute read
  • Earnings

Recap: Bicycle Therapeutics Q1 Earnings

By Benzinga Insights
May 4, 9:35 AM
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:00 AM. Here’s what…

BCYC

Read More
2 minute read
  • Analyst Ratings

Analyst Ratings for Bicycle Therapeutics

By Benzinga Insights
April 18, 11:01 AM
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BCYC

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target

By Benzinga Newsdesk
March 1, 7:17 AM
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target.

BCYC

Posts navigation

1 2 3 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service